APGE FINANCIAL STATEMENTS

Apogee Therapeutics, Inc. Common Stock — balance sheet, income statement and cash flow trends

APGEApogee Therapeutics, Inc. Common Stock

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value it Duel

Income Statement

Quarterly progression — trailing-twelve-month values

RevenueNet Income

Profit Funnel

Q1 2026 · TTM

Percentages are relative to revenue.

Key Figures

YoY change

Revenue0 $-100.0%

Gross Profit-808 K $—

Operating Income-305.3 M $—

EBITDA-272.7 M $—

Net Income-274.6 M $—

Peer Comparison· Biotechnology

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
APGE	-100.0%	—	—	—
CSL	4.8%	48.6%	32.8%	9.2%
TLX	56.3%	50.8%	3.0%	-0.9%
MSB	410.4%	-32.0%	-76.6%	-115.3%
Industry median	5.1%	84.0%	-105.8%	-125.7%

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
APGE	-100.0%	—	—	—
PTGX	-64.4%	99.5%	-153.8%	-154.9%
CORT	12.2%	98.3%	1.8%	6.2%
SMMT	—	—	—	—
IBRX	351.5%	93.8%	-515.2%	-606.2%
NUVL	—	—	—	—
Industry median	5.1%	84.0%	-105.8%	-125.7%

Balance Sheet

Quarterly period-end values

Total AssetsTotal LiabilitiesEquity

Capital Structure

Q1 2026

Equity1.3 B $97%
Current Liabilities33 M $3%
Long-term Liabilities4.9 M $0%

Key Figures

YoY change

Total Assets1.3 B $+81.1%

Total Liabilities37.9 M $-7.2%

Total Equity1.3 B $+86.5%

Cash & ST Investments1.1 B $+106.5%

Total Debt8 M $-31.9%

Net Debt-443.8 M $—

Peer Comparison· Biotechnology

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
APGE	32.59	0.6%	3.86	97.1%
CSL	2.57	67.4%	2.22	49.2%
TLX	1.43	112.3%	13.13	35.1%
MSB	—	—	—	—
Industry median	5.90	10.9%	1.15	70.0%

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
APGE	32.59	0.6%	3.86	97.1%
PTGX	17.76	1.5%	4.72	94.0%
CORT	2.86	1.5%	-23.21	78.3%
SMMT	7.41	3.7%	0.69	84.3%
IBRX	6.67	-129.3%	-1.02	-134.5%
NUVL	16.14	—	—	88.2%
Industry median	5.90	10.9%	1.15	70.0%

Cash Flow Statement

Quarterly progression — trailing-twelve-month values

Operating Cash FlowCapital ExpendituresFree Cash Flow

Cash Flow Bridge

Q1 2026 · TTM

Key Figures

YoY change

Operating Cash Flow-234.5 M $—

Capital Expenditures830 K $-83.8%

Free Cash Flow-235.4 M $—

Dividends Paid——

Peer Comparison· Biotechnology

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
APGE	—	—	—	85.4%
CSL	24.0%	20.3%	3.7%	261.5%
TLX	-2.2%	-6.3%	4.1%	243.1%
MSB	-87.7%	-90.0%	2.3%	76.1%
Industry median	-88.0%	-90.9%	1.9%	81.5%

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
APGE	—	—	—	85.4%
PTGX	-157.5%	-157.0%	3.5%	101.7%
CORT	15.6%	15.6%	0.0%	250.7%
SMMT	—	—	—	37.9%
IBRX	-208.8%	-212.3%	3.5%	34.5%
NUVL	—	—	—	69.5%
Industry median	-88.0%	-90.9%	1.9%	81.5%

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on APGE

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 2, 26. This content is for informational purposes only and is not investment advice.